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strategies for early rheumatoid arthritis: the first
three years
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Llewellyn Spargo3, Robert G Metcalf3, Cindy Hall3, Susanna M Proudman3,4 and Michael D Wiese1Abstract
Introduction: Treat-to-target (T2T) strategies using a protocol of pre-defined adjustments of disease-modifying
anti-rheumatic drugs (DMARDs) according to disease activity improve outcomes for patients with rheumatoid
arthritis (RA). However, successful implementation may be limited by deviations from the protocol. The aim of this
study was to determine the prevalence of protocol deviation, explore the reasons and identify subsets of patients
in whom treatment protocols are more difficult to follow.
Methods: In this retrospective cohort study, treatment-naïve patients with RA of less than one year’s duration,
attending a dedicated early arthritis clinic between 2001 and 2013, were followed for three years from initiation of
combination therapy with conventional DMARDs which was subsequently modified according to a T2T protocol. At
each clinic visit, whether deviation from the protocol occurred, the type of deviation and the reasons for deviation
were assessed. The relationship between protocol deviations and baseline variables was determined using linear
regression analysis.
Results: In total, 198 patients contributed 3,654 clinic visits. The prevalence of protocol deviations was 24.5% and
deviation in at least at one clinic visit was experienced by 90.4% of patients. The median time to first deviation was
30 weeks. Continuing existing treatment rather than intensifying therapy was the most common type of deviation
(59.9%). Patient and physician related factors were the most common reasons for deviation, each accounting for
24.7% of deviations, followed by toxicities (23.3%) and comorbidities (20.0%). The prevalence of protocol deviations
was lower among patients who achieved remission after three years (13.1%; 162 deviations out of 1,228 visits)
compared with those who were not in remission (30.9%; 523/1692) (P <0.0001). On multivariate analysis, only body
mass index (P = 0.003) and helplessness score (P = 0.04) were independent predictors of protocol deviations
although the predictive power of the model was not strong (R2 = 0.17).
Conclusions: Deviation from a T2T protocol occurred in one quarter of visits, indicating that applying the T2T
approach is feasible in clinical practice. Failure to escalate dose when indicated was commonly encountered, and
just under half of the observed deviations were related to either toxicities or comorbidities and were therefore
justifiable on clinical grounds.* Correspondence: nasir.wabe@unisa.edu.au
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Research, University of South Australia, GPO Box 2471, Adelaide 5001,
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Treating rheumatoid arthritis (RA) with disease modify-
ing anti-rheumatic drugs (DMARDs) according to a
treat-to-target (T2T) strategy is more effective than trad-
itional routine care [1-5]. In order to achieve rapid disease
control, disease activity is assessed regularly and drug
doses are escalated or new medications are added until a
predefined target disease activity state such as remission
or low disease-activity (LDA) is reached [6], in a manner
similar to management of other chronic diseases such as
diabetes and hypertension [7].
To date, little is known about deviation from T2T
recommendations and the reasons for these deviations
[8,9]. As the T2T strategy involves frequent assessments
of disease activity [10] and application of predefined
dose modification criteria (DMC), it may not be feasible
outside the clinical trial setting, or the benefits reported
in trials may not be realised in the clinic. Adherence to
T2T recommendations could be influenced by factors re-
lating to the patient, the physician, the disease, medication
or other co-morbid conditions. For example, a physician
could deviate from T2T recommendations if his or her as-
sessment of a patient’s disease activity status differed from
that determined by composite disease activity measures [9]
or patient preference could influence willingness to change
therapy when indicated [9-11]. Irreversible joint damage,
contraindications and/or past adverse drug reactions to
DMARDs, comorbidities and logistic issues are recognised
barriers to changing treatment in clinical practice [8].
Contemporary T2T protocols vary from setting to setting.
One or more classes of drugs, conventional DMARDs,
corticosteroids and biological agents could be included, and
the initial approach could be step-up, step-down or paral-
lel therapy. Assessing the extent of deviation from a T2T
protocol and the related factors would facilitate an evalu-
ation of the feasibility of the proposed recommendations
in clinical practice and increase awareness of common
reasons for protocol deviations.
The aims of this study were to determine the prevalence
of deviations from a T2T protocol in an early arthritis
clinic in which treatment-naïve patients with RA of less
than 12 months duration were treated with combination
therapy with conventional DMARDs. The type of devia-
tions and the reasons for them were examined and base-
line factors associated with deviation were identified.
Methods and patients
Setting and study design
Between September 2001 and December 2013, consecu-
tive patients attending the Royal Adelaide Hospital Early
Arthritis Clinic were included if they were diagnosed with
RA according to the 1987 revised American College of
Rheumatology (ACR) [12] or 2010 ACR/European League
Against Rheumatism (EULAR) criteria [13], and were 18years of age or older, with active disease (less than one
year duration) and DMARD-naïve. Those with less than
one year of follow up were excluded from this analysis,
and data for each patient over three years of follow up
were analysed. Ethics approval was obtained from the
Royal Adelaide Hospital Research Ethics Committee and
patients gave informed consent.
Initial treatment and follow up
All patients initially received triple therapy with methotrex-
ate (MTX) (10 mg/week), hydroxychloroquine (HCQ) (400
mg daily) and sulfasalazine (SSZ) (500 mg/day increasing
to 2 g over 4 weeks) (Table 1). Exceptions were patients
who were sensitive to sulphur-containing compounds
(where sulfasalazine was omitted) and/or any other dis-
ease known to increase the toxicity of these DMARDs.
Disease activity status was assessed at clinic visits every
3 to 6 weeks in the first three months then every 6 weeks
until the criteria to escalate dose (see below) were no lon-
ger fulfilled. Modification of therapy for toxicity occurred
at any time as clinically indicated. Parenteral adminis-
tration of corticosteroids was permitted to temporarily
reduce disease activity if required, and the use of oral
corticosteroids and non-steroidal anti-inflammatory drugs
was actively discouraged.
Dose modification criteria
Two approaches to escalating therapy were employed (cri-
teria-based or disease activity score in 28 joints (DAS28)-
based). Before 2009, dose modification was indicated if both
major (swollen joint counts (SJC) >1 and elevated erythro-
cyte sedimentation rate (ESR) or C-reactive protein (CRP))
or one major and two minor criteria (tender joint counts
(TJC) >1, morning stiffness >30 minutes, pain on visual
analogue scale (VAS) >30 mm, fatigue VAS >30 mm) were
fulfilled (criteria-based DMC) [2]. After 2009, the DMC
were based on a DAS28 target, whereby therapy was esca-
lated if DAS28 was >2.6 (DAS28-based DMC).
When DMC were fulfilled, dose escalation of an existing
agent or addition of a new DMARD was indicated accord-
ing to a structured algorithm (Table 1), unless adjustments
in medication were required for toxicity. Accordingly, after
maximal doses of MTX (25 mg/week via the parenteral
route) and SSZ (3 g/day) were prescribed, if disease activ-
ity targets were not met, leflunomide then other DMARDs
were added step by step (Table 1). After addition of
leflunomide, biological DMARDs could be added if the
Australian Pharmaceutical Benefits Scheme criteria were
fulfilled. DMARDs were not tapered or ceased unless tox-
icity occurred, even if sustained remission was achieved.
Clinic visits and assessment of disease activity
At baseline, the following information was collected: socio-
demographics (age, sex, smoking status), weeks since onset










Sulfasalazine (SSZ) Other DMARDs
0 10 mg/wk oral2 400 mg/d 0.5 g/d to 2.0 g/d3
6 Yes 10 mg/wk oral2 400 mg/d 3.0 g/d
12 Yes 15 mg/wk oral2 400 mg/d 3.0 g/d
18 Yes 20 mg/wk oral2 400 mg/d 3.0 g/d
24 Yes 25 mg/wk oral4 400 mg/d 3.0 g/d
30 Yes 25 mg/wk inj 400 mg/d 3.0 g/d LFN 10 mg#
36 Yes 25 mg/wk inj 400 mg/d 3.0 g/d LFN 20 mg
42 Yes 25 mg/wk inj 400 mg/d 3.0 g/d LFN 20 mg + gold inj 50 mg/wk
48 Yes 25 mg/wk inj 400 mg/d 3.0 g/d LFN 20 mg + gold inj 50 mg/wk +
Cyclosporine A 2.5 mg/kg5#
54 Yes 25 mg/wk inj 400 mg/d 3.0 g/d LFN 20 mg + gold inj 50 mg/wk +
Cyclosporine A 3 mg/kg
60 Yes 25 mg/wk inj 400 mg/d 3.0 g/d LFN 20 mg + gold inj 50 mg/wk +
Cyclosporine A 4 mg/kg#
66 Yes 25 mg/wk inj 400 mg/d 3.0 g/d LFN 20 mg + gold inj 50 mg/wk +
Cyclosporine A 4 mg/kg + azathioprine
1-2 mg/kg#
72 Yes If an inadequate response has occurred after 3 months, treatment failure
*Patients were reviewed at least every 6 weeks and therapy was increased if the treatment target had not been reached. Weeks of follow up are listed in the case
of continued disease activity and hence increase in therapy at every visit. #Biological DMARDs can be added, if Pharmaceutical Benefits Scheme criteria are
fulfilled. 1If dose modification criteria (DMC) are not fulfilled, treatment is not modified; 2MTX administered parenterally if gastrointestinal side effects, 3starting
dose 0.5 g/d and then increased by 0.5 g/d at weekly intervals to 2 g/d; 4maximum dose of MTX was based on weight and renal function: if weight <50 kg and/or
creatinine clearance >30 but <60, MTX 20 mg/wk orally or parenterally, and if weight >50 kg and creatinine clearance >60 ml/min, MTX 25 mg/kg orally or
parenterally. DMC, dose modification criteria; LFN, leflunomide; inj, injection.
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(RF) and anti-cyclic citrullinated peptide (anti-CCP) status
and body mass index (BMI). At every visit, patients com-
pleted a questionnaire that assessed fatigue (assessed by
100 mm-VAS; 100 = worst fatigue), patient global as-
sessment of disease (PGA) (100 mm VAS; 100 = worst
rating), pain (100 mm VAS; 100 = worst pain), helpless-
ness (assessed by rheumatology attitudes index (RAI)-
helplessness subscale) [14] and physical function (assessed
by modified health assessment questionnaire, mHAQ)
[15]. A single metrologist assessed SJC and TJC, and ESR
and CRP were measured. One of four rheumatologists
(AL, MDWe, LGC and SMP) or a rheumatology trainee
under their supervision provided an assessment of phys-
ician global assessment of disease (PhGA). Disease activity
was assessed according to the DAS28 based on the ESR
[16]. Quality of life (using rheumatoid arthritis quality
of life questionnaires, RAQoL) [17] and radiographic
status (van der Heide modified Sharp score read by
blinded assessors (MDWe and SMP)) [18] were recorded
annually. Data were extracted onto a structured data
collection form.
Protocol deviation
Adherence to the T2T protocol at every clinic visit over
the first 3 years and the proportion of all visits associatedwith protocol deviation was calculated. Protocol devia-
tions were defined according to Table 2.
To explore whether the prevalence of protocol deviation
changed over time, the prevalence in the periods between
baseline and 6 months, 6 to 12 months, 12 to 24 months,
and 24 to 36 months was determined. Similarly, deviations
were stratified according to baseline disease activity, and
patients were categorised as having LDA (DAS28 < 3.2),
moderate disease-activity (MDA) (DAS28 3.2 to 5.1) or
high disease-activity (had) (DAS28 > 5.1). Finally, devia-
tions were stratified according to DAS28 remission status
(that is, DAS28 < 2.6) after 3 years of treatment.
Pattern of deviations were characterized into five major
categories: no deviations, temporary-occasional (deviation
at just one clinic visit), temporary-relapsing (more than one
deviation but not at consecutive clinic visit), persistent-
occasional (deviation at more than one consecutive clinic
visits occurring once) and persistent-relapsing (persistent
deviation occurring more than once).
The type and nature of deviation were reported using
a similar approach to that employed by Vermeer, et al.
[9]. Accordingly, deviations were classified into one of five
categories: intensifying instead of continuing; continuing
instead of intensifying; tapering instead of continuing/in-
tensifying; discontinuation instead of continuing/intensify-
ing and any other cause. Intensifying instead of continuing







Yes No Intensified Continued/tapered/discontinued
Yes Yes Intensified2 Continued/tapered/discontinued3
No No Continued Intensified/tapered/discontinued
No Yes Continued/tapered/discontinued Intensified
Yes/no Yes/no Discontinuation of all DMARDs4
1Severe toxicities, according to physician’s assessment, deemed to be unfavourable to the health of the patient. Minor complaints were not considered as
significant toxicity; 2when the existing drug was withdrawn or dose reduced due to toxicity but the dose of another drug was increased or a new agent was
added, treatment was considered as intensified; 3if significant toxicity occurred; therapy escalation was not expected. However, it was considered a deviation as
the disease was still active (that is, dose escalation criteria fulfilled); 4stopping all disease-modifying anti-rheumatic drugs (DMARDs) regardless of patient’s disease
activity or toxicity status were considered deviation.
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of a new DMARD to the current regimen. Continuing in-
stead of intensifying means not modifying any of the com-
ponents of the existing regimen. Tapering was reducing
the dose of one or more DMARDs. Discontinuation was
defined as stopping one or more DMARDs for at least
one clinic visit.
For each deviation, the reasons were recorded and
categorised as toxicity, patient-related, physician-related,
comorbidity or other causes. Toxicities were classified ac-
cording to the physician’s assessment. Only significant tox-
icities (that is, those deemed to be unfavourable to the
health of the patient) were included in this definition. These
were then categorized according to the system affecte, for
example, gastrointestinal, haematological, central nervous
system, et cetera. Comorbidities were recorded from med-
ical charts and physician notes. These comprised any ser-
ious and/or ongoing medical condition.
Patient-related factors were classified as poor concord-
ance with therapy, reluctance to modify therapy and
other (including social issues such as relocation or family
problems). Concordance was based on patients’ self-
reports [19]. It was defined as continuing the same regi-
men regardless of a recommendation to intensify at the
previous visit, or when all or part of the medication regi-
men was ceased or tapered by the patient. Reluctance to
modify therapy was defined as unwillingness to escalate
the dose of existing drug or resistance to the addition of
new DMARD(s) when recommended by the physician.
Physician-related factors included a wait-and-see approach,
limited treatment options, persistent disease and other.
The wait-and-see approach applied to situations where the
physician delayed therapy adjustment until the next clinic
visit and waited to see if the current regimen would
achieve the desired effect at this later time. Limited
treatment options occurred when the options for add-
itional therapy were limited (that is, medications in the
DMARD algorithms (Table 1) were either all prescribed,
contraindicated, or there was a reluctance to initiate
more toxic and/or inconvenient therapies) and physiciansopted to continue the current regimen. Persistent disease
occurred when physicians used their clinical judgement to
intensify therapy even when DMC was not fulfilled.
Not all reasons for deviation from the protocol were
considered inappropriate, and reasons were considered to
be permissible (generally due to toxicities and/or comor-
bidities) and non-permissible protocol deviations (classi-
fied as patient, physician and other causes).
Statistical analysis
Data were analysed using Statistical Package for Social
Sciences (SPSS) for Windows version 21.0 (SPSS Inc.,
Chicago, IL, USA). Descriptive analyses were performed
for all continuous variables as mean with SD or median
with IQR if the data were not normally distributed.
Categorical variables were described according to the
frequency and percentage. The number and percentage
of visits associated with protocol deviations was deter-
mined for each patient and expressed as a total number
and mean (SD) or median (IQR).
Comparison of frequency of deviation across patient
groups (that is, criteria-based versus DAS28-based cohorts)
and baseline disease activity (HDA versus (LDA+MDA))
was assessed using the chi-square test. Because LDA was
uncommon at baseline (n = 10), this was combined with
MDA for the purpose of statistical analysis. The estimate
and CI for the difference in the proportion of visits with
a deviation/patient for two groups was based on the
Hodges-Lehman median difference. Analysis of time to
first protocol deviation was based on the Kaplan-Meier
estimate, and the log-rank test and Mantel-Cox P-values
were used to identify the statistical differences between
the two DMC. The Pearson product-moment correlation
coefficient (for two continuous variables) and a point bi-
serial correlation coefficient (for dichotomous and continu-
ous variables) were calculated to investigate correlation
between baseline factors and protocol deviations. Univari-
ate linear regression was then performed to determine
baseline factors affecting protocol deviations. Multiple lin-
ear regression analysis using the forced entry method was
Table 3 Baseline characteristics (n = 198 patients)
Female, n (%) 142 (71.7)
Age, years, median (IQR) 56.2 (44.6 to 66.5)
Body mass index (kg/m2),
median (IQR)
27.2 (24.0 to 30.8)
Current and former smoker, n (%) 107 (54.0)
Educational status, n (%)





Engaged in paid employment, n (%) 92 (46.5)
Duration of polyarthritis, weeks,
median (IQR)
16 (12 to 27)
Rheumatoid factor positive, n (%) 124 (62.6)
Anti-cyclic citrullinated peptide positive, n (%) 109 (56.2)




Low disease-activity, n (%) 10 (5.1)
Moderate disease-activity, n (%) 63 (32.3)
High disease-activity, n (%) 122 (62.6)
Physician global assessment of
disease activity, median (IQR)
54.0 (34.0 to 70.0)
Erosive disease, erosion score ≥1, n (%) 36 (23.5)
Sharp/van der Heijde score, median (IQR) 2.0 (0.0 to 7.0)
Modified health assessment questionnaire,
median (IQR)
0.63 (0.25 to 1.13)
Pain VAS, median (IQR) 57.0 (30.5 to 75.0)
Fatigue VAS, median (IQR) 50.5 (23.0 to 69.0)
Patient global assessment of disease
activity VAS, median (IQR)
49.0 (26.0 to 64.8)
Rheumatology attitudes index-helplessness
subscale, median (IQR)
14.0 (10.0 to 18.3)
Rheumatoid arthritis quality of life score,
median (IQR)
10.0 (5.7 to 15.0)
Started triple DMARD therapy at baseline, n (%) 175 (88.4)
*Trade school or not recorded. DAS28, disease activity score in 28 joints;
DMARD, disease modifying anti-rheumatic drug; Triple DMARD therapy =
methotrexate + sulfasalazine + hydroxychloroquine; VAS, visual analogue
scale score.
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Out of 231 patients who were initially considered for in-
clusion, a total of 198 patients completed at least one
year of follow up: these were 121 patients in the criteria-
based and 77 in the DAS28-based cohort. Of these, 198,
174, and 149 patients completed one, two and three
years, respectively. Baseline characteristics are presented
in Table 3: 33 patients were excluded due to being lost
to follow up (n = 21), having short follow up (10), or other
serious medical conditions (cancer and stroke, n = 2).
Triple DMARD therapy containing MTX, SSZ and
HCQ was the initial treatment in 175 (88.4%) patients.
About 93 (47%) initiated leflunomide, 24 (12.5%) gold, 4
(2.5%) cyclosporine, 2 (1.5%) azathioprine and 14 (7.1%)
biological agents, and only 5 (2.5%) were prescribed
more than three DMARDs at the end of follow up.
Prevalence of protocol deviation
There was a total of 3,654 clinic visits over the follow-up
period with a mean (SD) of 18.5 (6.0) visits per patient.
The mean (SD) number of clinic visits per patient during
the first, second and third years was 9.8 (2.0), 5.7 (2.2) and
4.9 (1.9), respectively. Deviation from the protocol oc-
curred in 896 of 3,654 (24.5%) visits (median of 4.0 (2.0 to
7.0) per patient). Deviation in at least one clinic visit was
experienced by 179 (90.4%) of the patients (Figure 1A).
Temporary deviations (n = 35) and relapsing occasional
deviation (n = 54) occurred in 44.9% (89 of 198) patients.
The remainder of the patients experienced either persist-
ent (n = 15, 7.6%) or recurrently persistent deviation (n =
75, 37.9%) (Figure 1B).
Clinic visits were more frequent (1,225 clinic visits), but
the percentage of visits with deviations was lowest (12.7%,
156 of 1,225 visits) during the first 6-months (P <0.0001).
As treatment progressed, the percentage of visits with de-
viations increased to 30.6% (216 of 706 visits), 29.0% (288
of 993 visits) and 32.3% (236 of 730 visits) in the periods 6
to 12, 12 to 24 and 24 to 36 months after treatment initi-
ation, respectively.
Protocol deviation according to DMC
Patients treated according to the criteria-based DMC
had a lower frequency of visits with a deviation com-
pared to patients treated according to the DAS28-based
protocol (23.4% versus 26.8%, median difference −4.2%
(95% CI −9.02 to 0.87), P = 0.016). When stratifying by
the period of treatment, there was no difference during the
first year of therapy, but patients treated according to
the DAS28-based approach experienced more deviationsduring the second (P <0.001) and third years (P = 0.025)
(Figure 1C).
Protocol deviation according to baseline disease activity
Patients with LDA/MDA at baseline experienced less
frequent deviations compared with patients with HDA at
baseline (20.1% versus 26.8%, median difference −6.3%
(95% CI −11.1 to −1.3%), P <0.0001), and they had
fewer deviations during the first (P <0.0001) and sec-
ond (P = 0.002) years of treatment, but there was no
difference in the third year (Figure 1D).
Figure 1 Number and pattern of deviations and deviations according to dose modification criteria (DMC) and baseline disease activity.
Percentage of patients versus number of deviations encountered (A) and pattern of deviations experienced (B). Mean (SD) percentage of visits
with deviation per patient in each year of treatment (C) by criteria used to inform dose modification and (D) by baseline disease activity. LDA,
low disease-activity; MDA, moderate disease-activity; DAS28, disease activity score in 28 joints.
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Patient and physician related factors were the most com-
mon reasons for protocol deviation, each accounting for
24.7% of total deviations, which were experienced by 107
(54.0%) and 103 (52.0%) patients, respectively (Tables 4
and 5). Just over half (56.7%) of protocol deviations were
categorised as non-permissible.
When patients with temporary deviations (n = 89) were
compared with patients experiencing persistent or recur-
rent deviations (n = 90), all reasons for deviation other thanphysician-related factors (P = 0.155) were significantly asso-
ciated with pattern of deviation. Accordingly, patients who
experienced deviations due to toxicities (odds ratio (OR),
95% CI: 5.7 (3.0 to 10.7), P <0.0001), comorbidities (OR,
95% CI: 9.6 (4.8 to 21.2), P <0.0001) and patient-related
reasons (OR, 95% CI: 3.6 (1.9 to 6.7), P <0.0001) were more
likely to experience persistent or recurrent deviations.
Overall, half of the patients (n = 99) experienced their
first protocol deviation by week 30 [median weeks to first
deviation, 95% CI = 30 (26.4 to 33.6) (Figure 2A)]. Time to













Toxicities 91 (46.0) 209 (23.3) 2 (1 to 3)
Co-morbidities 66 (33.3) 179 (20.0) 2 (1 to 4)
Non-permissible
Patient-related 107 (54.0) 221 (24.7) 2 (1 to 2)
Physician-related 103 (52.0) 221 (24.7) 2 (1 to 3)
Other 35 (17.7) 66 (7.3) 1 (1 to 2)
Total 179 (90.4) 896 (100.0) 4 (2 to 7)
As more than one reason can contribute to a deviation, the total number of
patients experiencing deviation is less than the total number of deviations.













Gastrointestinal 46 (23.2) 80 1 (1 to 2)
Haematological 25 (12.6) 61 2 (1 to 3)
Central nervous
system
26 (13.1) 35 1 (1 to 2)
Abnormal liver
function
18 (9.1) 28 1 (1 to 2)
Skin and hair 13 (6.6) 16 1 (1 to 1)
Fatigue 12 (6.1) 14 1 (1 to 1)
Muco-cutaneous 9 (4.5) 13 1 (1 to 2)
Other1 8 (4.0) 9 1 (1 to 1)
Comorbidities
Infection 28 (14.1) 45 1 (1 to 2)
Other co-morbidities2 51 (25.8) 134 2 (1 to 4)
Patient-related
Poor concordance 71 (35.9) 106 1 (1 to 2)
Reluctance to
modify therapy
48 (24.2) 94 1 (1 to 3)
Other3 20 (10.1) 21 1 (1 to 1)
Physician-related
Wait and see 50 (25.3) 95 1 (1 to 3)
Limited option 11 (5.6) 27 1 (1 to 5)
Persistent
disease4
14 (7.1) 15 2 (1 to 2)
Other5 65 (32.8) 84 1 (1 to 2)
Other6 35 (17.7) 66 (7.3) 1 (1 to 2)
1Respiratory, cardiovascular disease, weight loss et cetera; 2other muscle-skeletal
conditions such as osteoarthritis and fibromyalgia, respiratory disease, cancer and
pregnancy; 3social issues such as relocation or other problems; 4deviation related
to persistent disease activity was intensification when dose modification criteria
were not fulfilled; 5patient in remission, risk of toxicity, risk of flare et cetera;
6awaiting laboratory results, awaiting approval of biological disease modifiying
anti-rheumatic drugs (DMARDs), logistic reasons, prophylaxis for tuberculosis
before initiating biological DMARDs.
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criteria-based or DAS28-based DMC (26 vs 32 weeks, p =
0.797). By week 52, 147 (74.2%) had experienced at least
one episode of protocol deviation. A reason-specific sur-
vival plot by DMC is presented in Figure 2B-E.
Type of protocol deviation
Irrespective of DMC used, continuing instead of intensi-
fying therapy was the most common type of protocol de-
viation (59.9%, 537 of 896 deviations, Table 6).
Patients with HDA at baseline had a higher rate of de-
viation due to continuing instead of escalating therapy
(P <0.0001) and discontinuing instead of continuing/es-
calating (P =0.014) compared to those with LDA/MDA
at baseline.
Protocol deviation according to treatment response
Remission according to DAS28 (DAS28 < 2.6) was achieved
by 28.5% (43/152), 42.3% (77/182), 46.3% (76/164) and
46.4% (65/140) at 6 months, 12 months, 24 months and 36
months, respectively. Remission rates were higher in pa-
tients with baseline LDA/MDA, as compared with HDA, at
6 months (47.2 versus 17.3%, P <0.0001) and 12 months
(54.0 versus 36.1%, P = 0.021). At 24 and 36 months, how-
ever, differences did not reach statistical significance (54.4
versus 42.1%, P = 0.132 at 24 months and 55.3 versus
42.4%, P = 0.148 at 36 months). There were more clinic
visits for patients not in DAS28 remission compared with
those in DAS28 remission (mean (SD): 22.6 (4.7) versus
18.9 (3.6)). The prevalence of protocol deviation was lower
among patients who achieved remission (13.1%; 162
deviations out of 1,228 visits) compared with those who
did not (30.9%; 523/1692) (P <0.0001) (Figure 3A and B).
In both groups, non-permissible deviations were more
common than permissible deviations (that is, toxicity and
comorbidity); however, the proportion of deviations that
were non-permissible was lower among patients whoachieved remission compared with those who did not (8.0
versus 16.9%, P <0.0001) (Figure 3C and D).
The proportion of patients with a persistent/recurrent
deviation was significantly less in patients who achieved
remission as compared to patients who did not (20.0%
versus 69.3%, P <0.0001) (Figure 3E and F). Patients in
remission had a lower prevalence of deviations due to
toxicity (12.1 versus 34.3%, P <0.0001), comorbidities (12.1
versus 27.1%, P = 0.003), patient-factors (15.7 versus 37.9%,
P <0.0001) and other reasons (4.3 versus 15.7%, P = 0.003),
but deviations secondary to physician related factors were
not different between patients who did, and did not achieve
remission (23.6 versus 33.6%, P = 0.156).
Figure 2 (See legend on next page.)
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Figure 2 Survival function showing time to protocol deviation. Time to first deviations due to all reasons (A), due to toxicity (B), due to
comorbidity (C), due to patient related factors (D) and due to physician related factors (E). Censoring of observation has occurred at either 52,
104 or 156 weeks of therapy. The overall median survival cannot be computed for toxicity and comorbidity as survival exceeds 50% at the end of
the study. DAS28, disease activity score in 28 joints.
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The patient-reported outcome measures including mHAQ
(r = 0.22, P = 0.002), pain (r = 0.18, P = 0.015), fatigue (r =
0.21, P = 0.004), helplessness (r = 0.28, P <0.0001) and PGA
(r = 0.24, P = 0.001), and paid employment (r = −0.182, P =
0.010) were correlated with the total number of protocol
deviations. Body mass index (r = 0.29, P <0.0001), baseline
DAS28 (r = 0.18, P = 0.028), and TJC (r = 0.21, P = 0.003)
were also associated with the number of deviations. BMI,
DAS28, TJC, mHAQ, PGA, fatigue and helplessness were
associated with permissible deviations, whereas BMI
and helplessness were the only baseline variables that
were associated with non-permissible deviations. Using
multivariate analysis, BMI (β, 95% CI 0.78 (0.28 to 1.27),
P = 0.003) and helplessness (β, 95% CI 0.77 (0.03 to
1.50), P = 0.04) remained independent predictors of proto-
col deviations, but the predictive power of the model was
not strong (R2 = 0.17).
Discussion
In the context of routine clinical practice, deviations from a
T2T strategy according to predefined DMC for a cohort of
patients with recent onset RA occurred in approximately
25% of clinical visits. Of these deviations, 43.3% were justifi-
able on clinical grounds. The most common type of proto-
col deviation was failure to escalate dose when indicated,
which accounted for more than half of deviations.
The need for early referral and commencement of
DMARDs followed by close monitoring of disease activ-
ity requires frequent patient visits, which may be a bar-
rier to the T2T approach in clinical practice [20]. In our
cohort, patients attended an average of 6.2 and 9.8 visits
in the first 6 and 12 months following DMARD initiation
respectively, and as such, the need for frequent visits did
not appear to be an issue. However, 21 individuals were
lost to follow up. The concordance with T2T may have
been different in these patients for the same reasons
they failed to continue attending the clinic. As the aim
of this article was to evaluate ongoing issues with imple-
menting T2T strategy, we excluded these patients from
current analysis.
Frequent dose intensification shortly after DMARD ini-
tiation was particularly common in the DAS28-based
DMC group, which may have been due to increased phys-
ician awareness of the importance of early intensive man-
agement in recent years and/or the greater conviction
imbued by a well-recognised composite measure of dis-
ease activity. Furthermore, compared with the criteria-based DMC cohort, approximately 20% more visits ful-
filled the criteria for increasing therapy when the DAS28-
based DMC was used (data not shown). These latter
patients, therefore, progressed through the algorithm
more quickly, reaching the less attractive drug options
(that is, gold, cyclosporine and azathioprine) earlier, which
may be associated with more deviations (see Figure 1) due
to a reluctance to initiate medications that were perceived
to be more toxic, particularly after the first year. Also, with
more prolonged treatment there may be a greater likeli-
hood that the patient and possibly the physician will be
more tolerant of the status quo and less demanding in
their quest for solutions. Protocol deviation was also
higher among patients with HDA at baseline. These
patients experienced more continuation rather than es-
calation of therapy, which may have been due to their
experiencing more side effects from medications (data
not shown). The higher rate of deviation in patients
with HDA at baseline was contrary to our expectation
that there would be a high incidence of (rapid) intensifi-
cation instead of continuation when compared to pa-
tients with LDA/MDA. This impact of baseline disease
activity, however, declined over time. This was in line
with the influence of baseline disease activity on treatment
outcome, which also declined as treatment progressed.
The higher prevalence of deviation and the lower rate of
remission in patients with baseline HDA indicate the
extent to which protocol deviation translates into treat-
ment outcome.
In the DREAM remission-induction cohort, deviation
in at least one clinic visit was similar to our cohort (91.0
versus 90.4%), but the overall prevalence of deviations in
our cohort was lower (24.5% versus 30.7%) [9]. Further-
more, the rate of deviations in those who achieved re-
mission was 13.1% in this cohort compared to 19.0% in
the DREAM cohort, while in those who did not achieve
remission the corresponding rates were 30.9% and 42.1%
[9]. Difference in clinical settings, the nature of protocol
used (for example, biological DMARDs were used more
commonly in the DREAM cohort), patient characteristics
or cultural reasons may have resulted in differences in the
prevalence rate. Furthermore, the fact that there were
stable personnel in our cohort (for example, physicians
and a metrologist with standardisation of application of
the T2T protocol), may also explain the lower rate of devi-
ation in this study.
This study differs from earlier reports in three major
respects. First, long-term (up to three years) follow up in










Toxicity 33 26 59
Patient-related 92 63 155
Physician-related 83 60 143
Comorbidity 79 42 121
Other* 42 17 59
Total, n (%) 329 (58.1) 208 (63.0) 537 (59.9) 0.005
Tapered rather than
continuing/escalating
Toxicity 31 22 53
Patient-related 25 13 38
Physician-related 11 12 23
Comorbidity 4 3 7
Other* 1 0 2
Total, n (%) 72 (12.7) 50(15.2) 122 (13.6) 0.077
Discontinued rather than
continuing/escalating
Toxicity 68 28 96
Patient-related 20 5 25
Physician-related 0 0 0
Comorbidity 37 14 51
Other 0 0 0 0.076
Total, n (%) 125 (22.1) 47 (14.2) 172 (19.2)
Dose escalated rather
than continuing
Toxicity 0 0 0
Patient-related 2 0 2
Physician-related 29 20 49
Comorbidity 0 0 0
Other* 2 1 3
Total, n (%) 33 (5.8) 21 (6.4) 54 (6.1) 0.402
Other**
Toxicity 1 0 1
Patient-related 0 1 1
Physician-related 3 3 6
Comorbidity 0 0 0
Other* 3 0 3
Table 6 Type of protocol deviation (Continued)
Total, n (%) 7 (1.3) 4 (1.2) 11 (1.2) 0.843
Total deviation 566 330 896 0.016
*Examples of other type of protocol violation include awaiting laboratory
results, awaiting approval of biological disease modifying anti-rheumatic drugs,
prophylaxis for latent tuberculosis before initiating biologics, and other logistic
reasons or unknown reason. #Statistical tests based on the chi-square test
compared the frequency of responses (clinic visits with deviation versus
no deviation) between patient groups due to specific types of deviation.
**Unknown, addition of very high unusual dose or intensification of two or
more drugs at a time, intensifying instead of tapering/discontinuing.
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allowed identification of the stages of therapy when devi-
ation is more likely to occur, and the impact of duration of
therapy on the type of deviation that is likely to occur.
Second, we studied the pattern of protocol deviations,
which appears to have an important relationship with
outcome. For example, delaying a suggested recommended
change to therapy to the next visit (that is, temporary devi-
ations) may have little impact on the overall treatment out-
come. Furthermore, the prevalence of persistent/recurrent
deviations was low among patients in remission compared
with those in non-remission whose disease activity dictated
more frequent adjustments in treatment (Figure 3E). Devi-
ations due to comorbidity, toxicity or patient-related fac-
tors were more likely to have persistent deviations, whilst
physician-related factors did not differ between temporary
and persistent deviations. Interestingly, these relations also
extended to treatment outcome; DAS28 remission was less
likely among patients experiencing deviations due to tox-
icity, comorbidity, patient-related factors or other factors,
whereas physician-related factors did not have any impact
on long-term treatment outcome.
Finally, we also explored whether baseline characteris-
tics would predict the occurrence of protocol deviations,
but the only objective baseline factor associated with
protocol deviation was BMI. This has potential long-term
clinical implications. Increased BMI is correlated with
physical inactivity and greater risk of comorbid conditions
including diabetes, hypertension, cardiovascular disease
and other musculoskeletal symptoms, which may also
affect how RA is treated [21,22]. Other objective measures
such as baseline radiographic scores, laboratory values as
well as socio-demographic variables, including gender, age
and smoking habits, did not predict protocol deviation.
Most of the factors correlating with protocol deviations in
a univariate analysis, albeit weakly, were patient-reported
outcomes, which may not directly measure the patho-
physiological status of disease and can be biased by
other comorbid conditions [23]. On the other hand, de-
cisions about dose modification could be influenced by
patient-reported outcomes to the extent that they pro-
vide an indication of the life impact of disease and per-
sonal factors such as illness behaviours. Furthermore,
Figure 3 Protocol deviations according to treatment outcomes. Deviations by type (A, B), reason for deviations (C, D) and proportion of
patients facing different patterns of deviations according to disease activity in 28 joints (DAS28) remission status (E, F).
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ness could be mediated through several factors. For
example, patients with high levels of helplessness areknown to experience higher levels of anxiety, depres-
sion, low self-esteem, impaired activities of daily living,
low socioeconomic status and more symptoms such as
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to poor concordance with therapy and/or reduce patient
motivation to comply with a physician’s recommendation.Toxicities and comorbidities
Toxicity can restrict long-term utilization of DMARDs
[27] and accounted for 16.6% of total deviations in this
cohort (Table 6). After DMARD-induced toxicity, judi-
cious re-challenge or addition of new drugs should be a
gradual and individualised process to avoid recurrence
of unwanted effects. Gastrointestinal side effects, such as
nausea, vomiting, abdominal pain/cramps, anorexia and
diarrhea, were the leading drug-related safety issues re-
sponsible for deviations. These side effects are common
with all conventional DMARDs [28], in particular sulfa-
salazine, which has been previously reported in this co-
hort [29]. In addition, comorbidities are very common in
patients with RA [30], and can impact on physical func-
tion [31]. These comorbidities may be independent of or
related to RA and its treatment, and it is often difficult
to discriminate between these causes [32], but regardless
of this, withholding or reducing DMARDs until these
conditions have resolved was considered to be a justifi-
able reason for protocol deviation.Patient and physician point of view
In the current study, both patients and physicians con-
tributed equally to failure of adherence to a strict T2T
strategy. According to international T2T taskforce rec-
ommendations [6], the management of RA should be
based on a ‘shared decision between patient and phys-
ician’, and effective implementation is based on patients’
long-term commitment to therapy. However, full com-
mitment was not demonstrated in this study, as about
one quarter of all deviations (24.7% of total visits associ-
ated with deviations) were associated with patient-related
reasons, including unwillingness to escalate their current
treatment and poor concordance with previously agreed
therapy. While concordance was not evaluated systematic-
ally in this study, patient self-reported concordance with
therapy was used as a rough estimate of concordance rate,
although this is likely to overestimate the true concord-
ance level [19]. Poor concordance occurred when patients
remained on the same dose regardless of a recommenda-
tion to intensify at the previous visit, or when all or part of
the medication regimen was ceased or tapered by the pa-
tient. If this occurred, the physician had no choice but to
reinstate the earlier regimen instead of intensifying, even
when dose escalation was indicated. Systematically asses-
sing the extent of concordance with therapy in the context
of T2T and implementing tailored approaches to improv-
ing concordance with therapy is almost certainly critical
to the success of this strategy.Reluctance to modify therapy when indicated is a com-
mon phenomenon in RA. Wolfe and Michaud [11] re-
ported that a common preference of patients undergoing
long-term treatment for RA was maintenance of their
current status and treatment, rather than striving for
longer-term benefits with more intensive treatment, with
attendant risks of new toxicities [11]. Van Hulst et al. [33]
reported that factors that patients use to inform this deci-
sion are different from those used by clinicians. Current
disability status, motivation to get better, belief in their
physician, satisfaction with their current medications, and
current number of painful joints affect patients’ decision
to modify therapy [33]. Patients may make their own risk-
benefit assessment before making decisions about their
therapy, and therefore may need to be educated about the
importance of short-term disease control in improving
long-term treatment outcomes.
It may be difficult in practice to strictly comply with
rigid T2T principles given the heterogeneity of patient
populations and a tendency to individualise the approach.
For example, sometimes therapy was intensified if there
was a belief that disease was still active, even if a DMC
was not fulfilled. Similarly, components of DAS28 such as
ESR are not specific for RA disease activity, and disease
may be considered inactive if elevated ESR was thought to
be due to an unrelated cause. Such decisions based upon
clinical judgement rather than composite disease activity
measures are common practice [9,34,35], and may be con-
sidered rational and acceptable by physicians, but were
considered unacceptable protocol deviations in this study.
Another common approach practised by physicians is the
so-called wait-and-see policy, where the physician thinks
more time is needed for the drug to deliver optimal bene-
fit and dose escalation is delayed until the next visit and
beyond so as to minimise potential overtreatment. This
was considered an unacceptable deviation in this study,
and was especially common with leflunomide and gold in-
jections, although the latter can take up to 6 months to
produce maximal benefit [36].
The results of the current study should be interpreted
within the following methodological limitations. The data
for this analysis were compiled from various sources in-
cluding physicians’ correspondence, a database containing
information on patient characteristics, treatments and out-
comes and from other medical records, but complete
information from all visits may not be available. The fre-
quency of clinic visits varied between patients depending
on disease activity, and if patients failed to attend sched-
uled visits. In the case of the latter, non-concordance with
the T2T protocol could have been underestimated. Our
assessment of reasons for deviations was subjective and
sometimes reasons for deviations were overlapping/inter-
related, and as a result there is a potential for misclassi-
fication bias, including categorisation as permissible or
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bidities as a reason for deviation, patient baseline co-
morbidities and their impact were not systematically
assessed. For example, we did not evaluate the extent to
which the treatment protocol was difficult to follow
among patients with multiple comorbidities. Various
clinical guidelines that utilise T2T differ from each
other in certain aspects [10]. Because this study was
conducted in the context of local T2T guidelines, which
are based on parallel triple DMARD therapy, the find-
ings may not be generalizable to other treatment ap-
proaches such as step-down, step-up or monotherapy.
Despite these limitations, the study addressed important
issues concerning the extent of deviation from T2T rec-
ommendations, reasons for deviations, whether devia-
tions are justifiable or not and baseline factors affecting
deviation. Further work towards understanding how
T2T operates in daily practice and the relationship be-
tween compliance with treatment guidelines and short-
and long-term treatment outcomes is required. Other
unanswered questions in the setting of DMC being ful-
filled include whether either a new medication or increas-
ing the dose of an existing drug is more likely to be
associated with protocol deviation, the type of medication
most likely to contribute to deviations and whether strict
adherence to treatment guidelines, particularly early in
the course of disease, will prevent patients from requir-
ing expensive biological agents.
Conclusion
In conclusion, there was a low level of protocol deviation
when a T2T strategy was implemented in real-life clin-
ical practice. Just under half of the observed deviations
were considered permissible and were related to either
drug toxicity or patient comorbidities. Patients with high
baseline BMI and helplessness scores were more likely
to experience protocol deviations.
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